Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Fineline Cube Dec 20, 2025
Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Fineline Cube Dec 20, 2025
Company Drug

Innovent Biologics Initiates Phase III Trial for Mazdutide in OSA and Obesity

Fineline Cube Jun 16, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) announced the dosing of the first participant in China...

Company Drug

Abbisko Therapeutics Launches Clinical Study of FGFR4 Inhibitor in Advanced Hepatocellular Carcinoma

Fineline Cube Jun 16, 2025

Shanghai-based Abbisko Therapeutics Co., Ltd. (HKG: 2256) announced the dosing of the first patient in...

Company Deals

Dessight Biomedical Secures RMB 100M Series A Funding for Surgical Robot Development

Fineline Cube Jun 16, 2025

Hangzhou-based Dessight Biomedical, a provider of ultra-microsurgery precision solutions, has completed a Series A funding...

Company Drug

AstraZeneca Launches Truqap in China for PIK3CA/AKT1/PTEN-Altered Breast Cancer

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) announced the official commercial launch of Truqap (capivasertib) in...

Company Deals

CR Sanjiu Partners with HELP Therapeutics to Advance iPSC-based Heart Failure Therapy

Fineline Cube Jun 16, 2025

China-based CR Sanjiu (SHE: 000999), a state-owned pharmaceutical company, announced a partnership with Nanjing-based HELP...

Company Deals Hospital

Raffles Medical Partners with CQMU First Hospital to Enhance Healthcare Services

Fineline Cube Jun 16, 2025

Singapore-based Raffles Medical Group, a leading integrated healthcare provider with a broad presence in Asia,...

Company Deals

AstraZeneca and CSPC Pharma Collaborate on Novel Oral Drug Discovery

Fineline Cube Jun 16, 2025

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) and China’s CSPC Pharmaceutical Group Ltd (HKG: 1093)...

Company Deals

CF PharmTech Files for Hong Kong IPO to Expand Respiratory Disease Treatments

Fineline Cube Jun 16, 2025

China-based CF PharmTech, Inc., a specialist in inhalable drugs for respiratory diseases, has filed for...

Company Deals

Cloudbreak Pharma Files for Hong Kong IPO Amid Ophthalmic Drug Development

Fineline Cube Jun 16, 2025

Cloudbreak Pharma Inc. has submitted another initial public offering (IPO) filing to the Hong Kong...

Company Deals

Nona Biosciences Licenses HCAb Technology to Visterra for Biologic Development

Fineline Cube Jun 13, 2025

Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with...

Company Deals

BioNTech in Deal to Acquire CureVac for $1.25B to Boost Cancer mRNA Therapies

Fineline Cube Jun 13, 2025

Germany-based BioNTech SE (NASDAQ: BNTX) announced plans to acquire all outstanding shares of fellow German...

Company Drug

AbbVie’s Mavyret Gains FDA Approval for Acute HCV in Children and Adults

Fineline Cube Jun 13, 2025

US-based AbbVie (NYSE: ABBV) announced that the US Food and Drug Administration (FDA) has approved...

Company Drug

Zhaoke Ophthalmology’s TAB014 Receives BLA Review for wAMD Treatment

Fineline Cube Jun 13, 2025

China-based Zhaoke Ophthalmology Ltd (HKG: 6622) announced that its Biologic License Application (BLA) for TAB014,...

Company Deals

GSK Licenses Shigella Vaccine to Bharat Biotech for Low- and Middle-Income Countries

Fineline Cube Jun 13, 2025

UK-based GSK plc (NYSE: GSK) announced a licensing agreement with Bharat Biotech International Limited, an...

Company Drug

Merck Launches Phase III Trial for Quadrivalent Dengue Vaccine V181

Fineline Cube Jun 13, 2025

US-based Merck, Sharp & Dohme (MSD; NYSE: MRK) announced the launch of the Phase III...

Company Deals

NVIDIA and Novo Nordisk Collaborate to Accelerate AI-Driven Drug Discovery

Fineline Cube Jun 13, 2025

US chip manufacturer NVIDIA (NASDAQ: NVDA) announced a strategic collaboration with Danish pharmaceutical giant Novo...

Company Drug

Sanofi’s Rilzabrutinib Shows Promise in IgG4-Related Disease Trial

Fineline Cube Jun 13, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) announced positive results from a Phase II study of...

Company Deals

Bayer Extends Genomics Partnership With Broad Institute for Cardiology Research

Fineline Cube Jun 13, 2025

German pharmaceutical giant Bayer AG (ETR: BAYN) and the US-based Broad Institute Inc. announced a...

Company Deals

Bayzed Health Launches HK IPO to Expand Cancer Care Services

Fineline Cube Jun 13, 2025

China-based Bayzed Health Group Inc. (HKG: 2609), a private healthcare provider specializing in oncology, has...

Company Deals

TransThera Sciences Sets Hong Kong IPO at HKD13.15 Per Share

Fineline Cube Jun 13, 2025

China-headquartered TransThera Sciences (Nanjing) Inc. is preparing for an initial public offering (IPO) of 15.281...

Posts pagination

1 … 78 79 80 … 600

Recent updates

  • BeOne Medicines Names Dual Presidents in Leadership Overhaul
  • Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline
  • TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor
  • Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China
  • Novo Nordisk Submits CagriSema NDA for 20% Weight Loss in Obesity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

BeOne Medicines Names Dual Presidents in Leadership Overhaul

Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Company Drug

TransThera NDA Accepted for Tinengotinib in Cholangiocarcinoma After FGFR Inhibitor

Company Drug

Bio‑Thera NDA for VEGF‑A165 Antibody Targets $2B Wet AMD Market in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.